Néphrites tubulo-interstitielles aiguës secondaires à l’utilisation d’anticorps anti-PD1 et anti-CTLA4

Julie Bellière(Inserm), Stanislas Faguer(Hôpital Rangueil), Nicolás Meyer(Hôpitaux Universitaires de Strasbourg), S. Ollier(Institut universitaire du cancer de Toulouse Oncopole), David Ribes(Centre Hospitalier Universitaire de Toulouse), S. Boulinguez(Institut universitaire du cancer de Toulouse Oncopole), A. Délas(Institut universitaire du cancer de Toulouse Oncopole), Julien Mazières(Université Toulouse III - Paul Sabatier)
Néphrologie & Thérapeutique
September 1, 2016
10.1016/j.nephro.2016.07.185
Cited by 1

Related Papers

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2020|1.1k
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780